In collaboration with the University of Bergen, Norway, DCprime has established a preclinical mouse model to study DCP-001 vaccinations in monotherapy and in combination therapy settings. The collaboration is supported by the Horizon 2020 EU grant AML-VACCiN. At the 7th CCBIO Annual Symposium additional preclinical data sets were presented for DCprime’s lead program, DCP-001. The data supports key product characteristics and sheds additional light on the mechanism-of-action of DCP-001, a whole cell-based vaccine derived from the company’s proprietary DCOne® human leukemic cell line.
The presented data showed that DCP-001 was able to suppress tumor growth in humanized immunocompetent mice. The results also demonstrated that the transformation of DCOne leukemic cells into DCP-001 leads to an immunogenic shift. Whereas the parental leukemic cells were poorly immunogenic, DCP-001 proved highly immunogenic, making it an attractive cancer vaccine candidate. Furthermore, DCP-001 induced the production of a broad range of pro-inflammatory cytokines in peripheral blood mononuclear cells (PBMCs) derived from healthy donors.
For more information see